Boehringer Ingelheim Corporation China Profits from Sinopharm Deal

April 1, 2008 -- The China subsidiary of Boehringer Ingelheim, Shanghai Pharmaceuticals, said its 2007 revenues rose 46% to 697 million RMB ($95 million). BI China expects that its revenues will increase over the next five years until they reach 2.3 billion RMB ($327 million) in 2012. BI China implied the reason behind its year-over-year increase was a distribution deal that it signed in 2006 with the state-owned pharmaceutical giant Sinopharm. More details...